burosumab sold brand name crysvita human monoclonal antibody medication approved treatment xlinked hypophosphatemia tumorinduced european union united states burosumab indicated treatment adults children ages one year older xlinked hypophosphatemia xlh rare inherited form caused overproduction hormone called fibroblast growth factor bone cells responsible blocking phosphate reabsorption kidney suppression vitamin dependent phosphate absorption intestine due excess activity phosphate levels blood abnormally low hypophosphatemia affects constitution thus burosumab designed bind receptor inhibit excess activity hormone within bodymedical citation needed united states burosumab also approved treat people age two older tumorinduced osteomalacia tio rare disease characterized development tumors causing weakened softened tumors associated tio release fibroblast growth factor lowers phosphate trials injection site reactions common occurring patients generally mild severity resolved approved use european union february treat children one year age older adolescents growing skeletons xlinked hypophosphataemia radiographic evidence bone disease april us food drug administration fda approved burosumab intended purpose patients aged one year fda approval fell breakthrough therapy orphan drug fda considered firstinclass national institute health care excellence england wales raised concerns regarding incremental costeffectiveness new drug available simple discount drug developed ultragenyx collaborative license agreement kyowa hakko httpsenwikipediaorgwikiburosumab